Courses | AUA University

Topic

Core Curriculum Related Education

Title	Category	Credit	Event date	Price
Adjuvant Therapies for High-Risk Non-Metastatic Kidney Cancer Podcast (2023)		0.50 AMA PRA Category 1 Credit™ 0.50 Non-Physician Participation		$0.00	Based on the documented need for additional education in prostate cancer, bladder cancer, and kidney cancer, the AUA has developed AUA Expert Exchange Podcast: Discussions in GU Cancer. The 2023 AUA Expert Exchange Podcast: Discussions in GU Cancer is designed to address very specific learning opportunities and reach the urologic practitioners in an easy, flexible way with smaller, targeted updates. To address the educational needs of the urologic care team, this episode will focus on:
Advances in ADT Part II: A Guide for APPs Webcast (2023)		1.00 AMA PRA Category 1 Credit™ 1.00 Non-Physician Participation		$0.00	Based on the documented need from the AUA Advanced Prostate Cancer Global Needs Assessment, the AUA has created Advances in ADT: Part II: A Guide for APPs (2023), an educational offering to further update APPs on the latest advancements in androgen deprivation therapy (ADT) and prostate cancer treatment. This educational initiative is comprised of multiple formats, including a live course and on-demand webcast. This live virtual course, which is the cornerstone of the initiative features a multidisciplinary panel, engaging in a lively discussion.
Advances in ADT Part II: A Guide for Urologists Webcast (2023)		1.00 AMA PRA Category 1 Credit™ 1.00 Non-Physician Participation		$0.00	Based on the documented need from the AUA Advanced Prostate Cancer Global Needs Assessment, the AUA has created Advances in ADT: Part II: A Guide for Urologists (2023), an educational offering to further update urologists on the latest advancements in androgen deprivation therapy (ADT) and prostate cancer treatment.
Advances in ADT: Part II: A Guide for APPs (2023)		1.00 AMA PRA Category 1 Credit™ 1.00 Non-Physician Participation	09/26/2023	$0.00
Advances in ADT: Part II: A Guide for Urologists (2023)		1.00 AMA PRA Category 1 Credit™ 1.00 Non-Physician Participation	09/28/2023	$0.00
AUA Advanced Prostate Cancer Guidelines Webcast (2024)		2.00 AMA PRA Category 1 Credit™ 2.00 Non-Physician Participation		$0.00	This course will be comprehensive AUA Guidelines on advanced prostate cancer in the management and outcomes of men with advanced, metastatic and castrate-resistant prostate cancer (CRPC). The course will include risk stratification, germline testing, PET imaging, the use of androgen deprivation therapy in combination with novel androgen axis therapy and chemotherapy in men with newly diagnosed metastatic hormone-sensitive prostate cancer. Early treatment intensification and evidenced-based guidelines will be covered.
Chemotherapy and Immunotherapy for the Urologist and Advanced Practice Provider Webcast (2024)		2.00 AMA PRA Category 1 Credit™ 2.00 Non-Physician Participation		$0.00	This is a repeat course from prior years, with review of advanced and metastatic prostate, bladder and kidney cancer. Most recent treatment guidelines are reviewed along with the studies that support them. Different disease spaces in oncologic care are discussed, including the medications used to treat them, their mechanism, side effects and efficacy. Role of the advanced practice provider is discussed for each tumor type. Finally, cases are presented along with management options for audience participation.
Disparities in Care and Barriers to Access for Patients with Advanced Prostate Cancer Podcast (2023)		0.50 AMA PRA Category 1 Credit™ 0.50 Non-Physician Participation		$0.00	Based on the documented need from the AUA Advanced Prostate Cancer Global Needs Assessment, the AUA is offering phase two of an educational series to update urologists and advanced practice providers (APPs) on the latest advancements in androgen deprivation therapy (ADT) and prostate cancer treatment. Part II will consist of two live webinars, one designed specifically for urologists and the other for APPs. The live virtual courses will feature a multidisciplinary panel engaging in a lively discussion on this topic.
Early Detection of Prostate Cancer: AUA/SUO Guideline Podcast (2023)		0.50 AMA PRA Category 1 Credit™ 0.50 Non-Physician Participation		$0.00	Based on the documented need for additional education in prostate cancer, bladder cancer, and kidney cancer, the AUA has developed AUA Expert Exchange Podcast: Discussions in GU Cancer. The 2023 AUA Expert Exchange Podcast: Discussions in GU Cancer is designed to address very specific learning opportunities and reach the urologic practitioners in an easy, flexible way with smaller, targeted updates. To address the educational needs of the urologic care team, this episode will focus on:Early Detection of Prostate Cancer: AUA/SUO Guideline (2023)
Genetics and Genomics of Urological Cancers - Current Guidelines and Case-based Discussion to Guide Clinical Practice Webcast (2024)		2.00 AMA PRA Category 1 Credit™ 2.00 Non-Physician Participation		$0.00	This case-based interactive course describes the role of germline genetics in urological cancers and how the identification of an alteration may impact precision oncology. We will provide a concise and comprehensive review of hereditary cancer genetics, discuss genetic risk assessment, diagnosis and treatment for a range of hereditary kidney, adrenal, upper tract and prostate cancer syndromes. We will review current National Comprehensive Cancer Network and AUA Guidelines for genetic evaluation of patients with kidney, adrenal, upper tract and prostate cancers.
Germline Testing and Novel Approaches to Targeting Genetic Mutations in Prostate Cancer Podcast (2023)		0.50 AMA PRA Category 1 Credit™ 0.50 Non-Physician Participation		$0.00	Based on the documented need for additional education in prostate cancer, bladder cancer, and kidney cancer, the AUA has developed AUA Expert Exchange Podcast: Discussions in GU Cancer. The 2023 AUA Expert Exchange Podcast: Discussions in GU Cancer is designed to address very specific learning opportunities and reach the urologic practitioners in an easy, flexible way with smaller, targeted updates. To address the educational needs of the urologic care team, this episode will focus on:
Germline Testing in GU Cancers – How I Do It Podcast (2023)		0.50 AMA PRA Category 1 Credit™ 0.50 Non-Physician Participation		$0.00	Based on the documented need for additional education in prostate cancer, bladder cancer, and kidney cancer, the AUA has developed AUA Expert Exchange Podcast: Discussions in GU Cancer. The 2023 AUA Expert Exchange Podcast: Discussions in GU Cancer is designed to address very specific learning opportunities and reach the urologic practitioners in an easy, flexible way with smaller, targeted updates. To address the educational needs of the urologic care team, this episode will focus on:Germline Testing in GU Cancers – How I Do It (2023)
Global Advancements in Bladder Cancer Webcast (2023)		1.50 AMA PRA Category 1 Credit™ 1.50 Non-Physician Participation		$0.00
How to use Prostate-Specific Membrane Antigen-Positron Emission Tomography/CT in the Management of Relapsing Prostate Cancer Patients following Local...		2.00 AMA PRA Category 1 Credit™ 2.00 Non-Physician Participation		$0.00	The learners will understand the following critical clinical aspects with regard to the clinical application of prostate-specific membrane antigen (PSMA) PET/CT; scanning mode of action of PSMA PET/CT; pitfalls of PSMA PET/CT; diagnostic accuracy depending on PSA, PSA double time, prostate cancer histology; application of PSMA PET/CT to identify patients with intrapelvic nodal relapse who will benefit from local therapy such as salvage lymphadenectomy or stereotactic radiation therapy; application of PSMA PET/CT to identify patients with organ-confined radiorecurrent local relapse of prosta
Incorporating Genomic Testing and Advanced Imaging For Prostate Cancer Into Your Practice Webcast (2024)		2.00 AMA PRA Category 1 Credit™ 2.00 Non-Physician Participation		$0.00	There are multiple genomic tests and advanced imaging modalities (MRI, prostate-specific membrane antigen PET, etc.) currently available for men to detect and risk-stratify prostate cancer. The outcomes of these tests may lead to different detection strategies (observation, immediate biopsy, etc.) and treatment decisions (active surveillance, surgery, radiation, adjuvant therapy, etc.). We will also discuss germline testing as inherited mutations have considerable implications for screening, treatment, genetic counseling and cascade testing of family members.

Pages